Table 2.
Weighted Arithmetic Means of Outcome Scores at Weeks 4-104 of Follow-up, Based on the Results of Studies Using LR-PRP Versus LP-PRP a
| VAS | ΔVAS | DASH | ΔDASH | PRTEE | ΔPRTEE | MAYO | ΔMAYO | |
|---|---|---|---|---|---|---|---|---|
| Baseline | ||||||||
| LR-PRP | 7.28 ± 1.60 (181) b | — | 63.2 ± 19.5 (81) b | — | 59.0 ± NR (166) | — | 52.0 ± 16.0 (67) b | — |
| LP-PRP | 6.61 ± 1.94 (137) | — | 48.8 ± 15.0 (212) | — | 56.0 ± 5.6 (93) | — | 63.2 ± 10.2 (15) | — |
| 4 wk | ||||||||
| LR-PRP | 4.63 ± 2.32 (168) c | 2.65 d | 43.1 ± 21.6 (51) c | 20.1 d | 49.0 ± NR (162) | 10 | 71.7 ± 16.0 (67) c | 19.7 d |
| LP-PRP | 5.49 ± 1.75 (77) c | 1.12 | 38.0 ± 20.1 (88) c | 10.8 | 42.3 ± 19.6 (55) c | 13.7 d | 78.3 ± 10.4 (15) c | 15.1 d |
| 8 wk | ||||||||
| LR-PRP | 3.57 ± 2.35 (132) c | 3.71 d | 37.2 ± 24.7 (51) c | 26.0 d | 31.3 ± NR (162) | 27.7 d | 79.5 ± 12.0 (31) c | 27.5 d |
| LP-PRP | 3.97 ± 2.11 (56) c | 2.64 d | 28.9 ± 19.1 (94) c | 19.9 d | 31.8 ± 20.9 (38) c | 24.2 d | NR | NR |
| 12 wk | ||||||||
| LR-PRP | 2.27 ± 2.10 (145) c | 5.01 d | 24.4 ± 22.0 (81) c | 38.8 d | 24.0 ± NR (151) | 35 d | NR | NR |
| LP-PRP | 4.05 ± 2.14 (70) c | 2.56 d | 24.0 ± 19.0 (30) c | 24.8 d | NR | NR | 84.7 ± 9.2 (15) c | 21.5 d |
| 24 wk | ||||||||
| LR-PRP | 2.32 ± 2.87 (146) c | 4.96 d | 27.8 ± 24.7 (51) c | 35.4 d | 14.4 ± NR (106) | 44.6 d | 81.2 ± 16.0 (31) c | 29.2 d |
| LP-PRP | 2.96 ± 1.94 (93) c | 4.96 d | 20.2 ± 17.0 (144) c | 28.6 d | 23.2 ± 18.2 (38) c | 32.8 d | 88.8 ± 8.4 (15) c | 25.6 d |
| 52 wk | ||||||||
| LR-PRP | 1.98 ± 2.84 (132) c | 5.30 d | 20.0 ± 23.5 (51) c | 43.2 d | 9.0 ± NR (50) | 50.0 d | 78.2 ± 18.0 (31) c | 26.2 d |
| LP-PRP | 1.98 ± 1.91 (97) c | 4.63 d | 14.4 ± 18.5 (110) c | 34.4 d | NR | NR | 92.8 ± 6.0 (15) c | 29.6 d |
| 104 wk | ||||||||
| LR-PRP | 4.58 ± 2.80 (101) c | 2.57 d | 17.6 ± 24.0 (51) c | 45.6 d | 69.2 ± NR (50) | –10.2 | NR | NR |
| LP-PRP | 0.90 ± 1.60 (31) c | 5.71 d | 5.5 ± 9.5 (31) c | 43.3 d | 15.9 ± 4.1 (31) c | 40.1 d | NR | NR |
a Data are reported as weighted arithmetic mean ± SD (No. of patients) unless otherwise indicated. References: LR-PRP, 14, 18, 19, 23, 24, 30, 38; LP-PRP, 1, 3, 12, 21, 22, 25, 37. DASH, Disabilities of the Arm, Shoulder and Hand; LP, leukocyte-poor; LR, leukocyte-rich; MAYO, Mayo Clinic Performance Index; NR, not reported; PRP, platelet-rich plasma; PRTEE, Patient-Rated Tennis Elbow Evaluation; VAS, visual analog scale for pain. Dashes indicate no difference.
b Statistically significant difference between LR-PRP and LP-PRP (P < .008).
c Statistically significant difference versus baseline (P < .004).
d Difference in score is greater than minimal clinically important difference.